Provided herein are microfluidic devices that can be configured to generate an electrophoretic flow that is in opposition to a fluid flow through a microcapillary of a microfluidic device provided herein. Also provided herein are methods that include adding an amount of particle to the inlet area of a microfluidic device as provided herein, generating a first fluid flow through a microcapillary of a microfluidic device provided herein; and applying a uniform electric field to the microfluidic device, where the uniform electric field generates an electrophoretic flow that is in opposition to the fluid flow.

Provided herein are methods for quantifying foreign cell-free DNA (cfDNA) via SNP profiling of low-volume blood sample. The methods allow for monitoring the status of organ transplant rejection through analysis of small volumes of patient capillary blood samples collected non-invasively with fingersticks or other devices. The methods also allow for guiding the dosage of immunosuppressant and for preparing for a new organ transplant in case of imminent organ failure.

Provided herein are methods for quantifying foreign cell-free DNA (cfDNA) via SNP profiling of low-volume blood sample. The methods allow for monitoring the status of organ transplant rejection through analysis of small volumes of patient capillary blood samples collected non-invasively with fingersticks or other devices. The methods also allow for guiding the dosage of immunosuppressant and for preparing for a new organ transplant in case of imminent organ failure.

A method of capillary electrophoresis is provided for binder selection. In an embodiment, a capillary electrophoresis method comprises selecting an electroosmotic flow (EOF) in a capillary such that at least one target-binder (TB) complex has a target-binder velocity vector (vTB) co-directed with an electric field vector (E) and at least one non-binder (N) has a non-binder velocity vector (vN) in the opposite direction to the electric field vector (E); introducing a sample comprising the at least one target-binder (TB) complex, the at least one non-binder (N), and at least one running buffer into a capillary inlet of the capillary; applying an electric field directed from the capillary inlet to a capillary outlet of the capillary to separate the at least one target-binder (TB) complex from the at least one non-binder (N); and detecting the at least one target-binder complex.

A method of capillary electrophoresis is provided for binder selection. In an embodiment, a capillary electrophoresis method comprises selecting an electroosmotic flow (EOF) in a capillary such that at least one target-binder (TB) complex has a target-binder velocity vector (vTB) co-directed with an electric field vector (E) and at least one non-binder (N) has a non-binder velocity vector (vN) in the opposite direction to the electric field vector (E); introducing a sample comprising the at least one target-binder (TB) complex, the at least one non-binder (N), and at least one running buffer into a capillary inlet of the capillary; applying an electric field directed from the capillary inlet to a capillary outlet of the capillary to separate the at least one target-binder (TB) complex from the at least one non-binder (N); and detecting the at least one target-binder complex.

The invention provides compositions comprising nucleic acid complexes for use in monitoring binding interactions and in measuring association and/or dissociation kinetics, detecting analytes including low concentration analytes, and screening library members. In some instances, the nucleic acid complexes are double-stranded nicked nucleic acids comprising a scaffold nucleic acid hybridized to one or more oligonucleotides. In some instances, a first, a second, a third, and optionally a fourth oligonucleotide are linked to moieties that are known to interact with each other or which are suspected of interacting with each other or of interacting with a common moiety such as an analyte. Changes in topology of the complex are used to determine the binding interactions of the various binding partners.

The invention provides compositions comprising nucleic acid complexes for use in monitoring binding interactions and in measuring association and/or dissociation kinetics, detecting analytes including low concentration analytes, and screening library members. In some instances, the nucleic acid complexes are double-stranded nicked nucleic acids comprising a scaffold nucleic acid hybridized to one or more oligonucleotides. In some instances, a first, a second, a third, and optionally a fourth oligonucleotide are linked to moieties that are known to interact with each other or which are suspected of interacting with each other or of interacting with a common moiety such as an analyte. Changes in topology of the complex are used to determine the binding interactions of the various binding partners.

The present invention is directed to a method for determining of at least one microsatellite instability (MSI) based on a shift in a capillary electrophoresis (CE) profile (CE profile shift), the CE profile shift being determined by a comparison between the capillary electrophoresis (CE) profile of a target sequence of at least one microsatellite (MSI target profile) and the capillary electrophoresis (CE) profile of its specific wild type sequence (MS wild type profile). Further, the invention encompass suitable primer for use in said method, a kit comprising all essential components for performing said method successfully, a complete closed device as a system, namely “MSI Modaplex Analysis System” and a method for diagnosis of MSI phenotypes associated with an inflammation, cancer, inflammation associated cancer and/or auto immune disease, wherein the diagnosis comprises the method for determining of at least one CE profile shift as mentioned above. Finally, the present invention is directed to the use of an improved MSI panel for the determination and preferably diagnosis of MSI tumors, said panel consist of the STR biomarker NR-21, NR-24, Mono27, D2S123, D5S346, D17S250, Bat-25 and Bat-26.

The present invention is directed to a method for determining of at least one microsatellite instability (MSI) based on a shift in a capillary electrophoresis (CE) profile (CE profile shift), the CE profile shift being determined by a comparison between the capillary electrophoresis (CE) profile of a target sequence of at least one microsatellite (MSI target profile) and the capillary electrophoresis (CE) profile of its specific wild type sequence (MS wild type profile). Further, the invention encompass suitable primer for use in said method, a kit comprising all essential components for performing said method successfully, a complete closed device as a system, namely “MSI Modaplex Analysis System” and a method for diagnosis of MSI phenotypes associated with an inflammation, cancer, inflammation associated cancer and/or auto immune disease, wherein the diagnosis comprises the method for determining of at least one CE profile shift as mentioned above. Finally, the present invention is directed to the use of an improved MSI panel for the determination and preferably diagnosis of MSI tumors, said panel consist of the STR biomarker NR-21, NR-24, Mono27, D2S123, D5S346, D17S250, Bat-25 and Bat-26.

Compositions, testing chambers and methods for testing a fuel sample for microbial contamination (including fuels treated with a biocide) are provided, which comprise: a quantity of hydrocarbon fuel; a microbial contamination wherein the microbial contamination further comprises nucleic acid in the form of both DNA, RNA or a combination thereof, and an analyzing solution; wherein the analyzing solution comprises at least six (6) primer pairs for amplification of at least one target locus, wherein at least one primer of each pair of primers is labeled with a fluorescent dye and wherein at least one of the primer pair binds to the nucleic acid of the microbial contamination.